<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20240409180720
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20240409180720" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 09 Apr 2024 22:07:23 +0000</lastbuilddate>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Macroscopic findings of severe structural valve deterioration of a transcatheter aortic bioprosthesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38592469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae228. doi: 10.1093/eurheartj/ehae228. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38592469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38592469</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae228>10.1093/eurheartj/ehae228</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38592469</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Paula Ackermann</dc:creator>
<dc:creator>Mohamed Abdel-Wahab</dc:creator>
<dc:creator>Thilo Noack</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Macroscopic findings of severe structural valve deterioration of a transcatheter aortic bioprosthesis</dc:title>
<dc:identifier>pmid:38592469</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae228</dc:identifier>
</item>
<item>
<title>Charting new frontiers in paediatric cardiomyopathies: lessons from the ESC EORP Cardiomyopathy and Myocarditis Registry in paediatric age</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38592468/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae143. doi: 10.1093/eurheartj/ehae143. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38592468/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38592468</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae143>10.1093/eurheartj/ehae143</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38592468</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Jolanda Sabatino</dc:creator>
<dc:creator>Werner Budts</dc:creator>
<dc:creator>Giovanni Di Salvo</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Charting new frontiers in paediatric cardiomyopathies: lessons from the ESC EORP Cardiomyopathy and Myocarditis Registry in paediatric age</dc:title>
<dc:identifier>pmid:38592468</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae143</dc:identifier>
</item>
<item>
<title>Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38592444/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The findings show that earlier diagnosis of AF is associated with a higher hazard ratio of subsequent myocardial disease and shorter life expectancy. Further studies are needed to determine causality and whether AF could be used as a risk marker among particularly younger patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae216. doi: 10.1093/eurheartj/ehae216. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients with atrial fibrillation (AF) are at increased risks of cardiovascular diseases and mortality, but risks according to age at diagnosis have not been reported. This study investigated age-specific risks of outcomes among patients with AF and the background population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This nationwide population-based cohort study included patients with AF and controls without outcomes by the application of exposure density matching on the basis of sex, year of birth, and index date. The absolute risks and hazard rates were stratified by age groups and assessed using competing risk survival analyses and Cox regression models, respectively. The expected differences in residual life years among participants were estimated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study included 216 579 AF patients from year 2000 to 2020 and 866 316 controls. The mean follow-up time was 7.9 years. Comparing AF patients with matched controls, the hazard ratios among individuals ≤50 years was 8.90 [95% confidence interval (CI), 7.17-11.0] for cardiomyopathy, 8.64 (95% CI, 7.74-9.64) for heart failure, 2.18 (95% CI, 1.89-2.52) for ischaemic stroke, and 2.74 (95% CI, 2.53-2.96) for mortality. The expected average loss of life years among individuals ≤50 years was 9.2 years (95% CI, 9.0-9.3) years. The estimates decreased with older age.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The findings show that earlier diagnosis of AF is associated with a higher hazard ratio of subsequent myocardial disease and shorter life expectancy. Further studies are needed to determine causality and whether AF could be used as a risk marker among particularly younger patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38592444/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38592444</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae216>10.1093/eurheartj/ehae216</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38592444</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Christian Paludan-Müller</dc:creator>
<dc:creator>Oliver B Vad</dc:creator>
<dc:creator>Niels K Stampe</dc:creator>
<dc:creator>Søren Z Diederichsen</dc:creator>
<dc:creator>Laura Andreasen</dc:creator>
<dc:creator>Laia M Monfort</dc:creator>
<dc:creator>Emil L Fosbøl</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Christian Torp-Pedersen</dc:creator>
<dc:creator>Jesper H Svendsen</dc:creator>
<dc:creator>Morten S Olesen</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality</dc:title>
<dc:identifier>pmid:38592444</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae216</dc:identifier>
</item>
<item>
<title>Inflammatory cardiomyopathy: searching an infrequent cause</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38591724/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae213. doi: 10.1093/eurheartj/ehae213. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38591724/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38591724</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae213>10.1093/eurheartj/ehae213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38591724</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Omar Gómez-Monterrosas</dc:creator>
<dc:creator>David Martínez-Juárez</dc:creator>
<dc:creator>Jordi Miró</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inflammatory cardiomyopathy: searching an infrequent cause</dc:title>
<dc:identifier>pmid:38591724</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae213</dc:identifier>
</item>
<item>
<title>Use of new and emerging cancer drugs: what the cardiologist needs to know</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38591670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>The last decade has witnessed a paradigm shift in cancer therapy, from non-specific cytotoxic chemotherapies to agents targeting specific molecular mechanisms. Nonetheless, cardiovascular toxicity of cancer therapies remains an important concern. This is particularly relevant given the significant improvement in survival of solid and haematological cancers achieved in the last decades. Cardio-oncology is a subspecialty of medicine focusing on the identification and prevention of cancer...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae161. doi: 10.1093/eurheartj/ehae161. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The last decade has witnessed a paradigm shift in cancer therapy, from non-specific cytotoxic chemotherapies to agents targeting specific molecular mechanisms. Nonetheless, cardiovascular toxicity of cancer therapies remains an important concern. This is particularly relevant given the significant improvement in survival of solid and haematological cancers achieved in the last decades. Cardio-oncology is a subspecialty of medicine focusing on the identification and prevention of cancer therapy-related cardiovascular toxicity (CTR-CVT). This review will examine the new definition of CTR-CVT and guiding principles for baseline cardiovascular assessment and risk stratification before cancer therapy, providing take-home messages for non-specialized cardiologists.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38591670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38591670</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae161>10.1093/eurheartj/ehae161</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38591670</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Iacopo Fabiani</dc:creator>
<dc:creator>Michela Chianca</dc:creator>
<dc:creator>Alberto Aimo</dc:creator>
<dc:creator>Michele Emdin</dc:creator>
<dc:creator>Susan Dent</dc:creator>
<dc:creator>Antonella Fedele</dc:creator>
<dc:creator>Carlo Maria Cipolla</dc:creator>
<dc:creator>Daniela Maria Cardinale</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Use of new and emerging cancer drugs: what the cardiologist needs to know</dc:title>
<dc:identifier>pmid:38591670</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae161</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in cardio-oncology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38591649/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae194. doi: 10.1093/eurheartj/ehae194. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38591649/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38591649</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae194>10.1093/eurheartj/ehae194</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38591649</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Joerg Herrmann</dc:creator>
<dc:creator>Teresa López-Fernández</dc:creator>
<dc:creator>Alexander R Lyon</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in cardio-oncology</dc:title>
<dc:identifier>pmid:38591649</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae194</dc:identifier>
</item>
<item>
<title>Infection, inflammation, and cardiovascular risk: are we underestimating an old disease?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38591639/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae104. doi: 10.1093/eurheartj/ehae104. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38591639/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38591639</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae104>10.1093/eurheartj/ehae104</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38591639</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Natalie Arnold</dc:creator>
<dc:creator>Wolfgang Koenig</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Infection, inflammation, and cardiovascular risk: are we underestimating an old disease?</dc:title>
<dc:identifier>pmid:38591639</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae104</dc:identifier>
</item>
<item>
<title>Calmodulin, sudden death, and the Folbigg case: genes in court</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38591620/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae152. doi: 10.1093/eurheartj/ehae152. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38591620/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38591620</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae152>10.1093/eurheartj/ehae152</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38591620</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Peter J Schwartz</dc:creator>
<dc:creator>Lia Crotti</dc:creator>
<dc:creator>Mette Nyegaard</dc:creator>
<dc:creator>Michael Toft Overgaard</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Calmodulin, sudden death, and the Folbigg case: genes in court</dc:title>
<dc:identifier>pmid:38591620</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae152</dc:identifier>
</item>
<item>
<title>Social Determinants of Cardiovascular Health: understanding their impact and transitioning to a holistic care approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38591554/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae012. doi: 10.1093/eurheartj/ehae012. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38591554/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38591554</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae012>10.1093/eurheartj/ehae012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38591554</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Achamyeleh Birhanu Teshale</dc:creator>
<dc:creator>Htet Lin Htun</dc:creator>
<dc:creator>Lachlan Dalli</dc:creator>
<dc:creator>Rosanne Freak-Poli</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Social Determinants of Cardiovascular Health: understanding their impact and transitioning to a holistic care approach</dc:title>
<dc:identifier>pmid:38591554</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae012</dc:identifier>
</item>
<item>
<title>Inorganic nitrate: a game changer in preventing contrast-associated acute kidney injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38591523/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae094. doi: 10.1093/eurheartj/ehae094. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38591523/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38591523</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae094>10.1093/eurheartj/ehae094</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38591523</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Carmine Zoccali</dc:creator>
<dc:creator>Francesca Mallamaci</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inorganic nitrate: a game changer in preventing contrast-associated acute kidney injury</dc:title>
<dc:identifier>pmid:38591523</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae094</dc:identifier>
</item>
<item>
<title>Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38591192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 9:ehae225. doi: 10.1093/eurheartj/ehae225. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38591192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38591192</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae225>10.1093/eurheartj/ehae225</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38591192</guid>
<pubDate>Tue, 09 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregory Y H Lip</dc:creator>
<dc:creator>Julius Nikorowitsch</dc:creator>
<dc:creator>Susanne Sehner</dc:creator>
<dc:creator>Nina Becher</dc:creator>
<dc:creator>Emanuele Bertaglia</dc:creator>
<dc:creator>Carina Blomstrom-Lundqvist</dc:creator>
<dc:creator>Axel Brandes</dc:creator>
<dc:creator>Vincent Beuger</dc:creator>
<dc:creator>Melanie Calvert</dc:creator>
<dc:creator>A John Camm</dc:creator>
<dc:creator>Gregory Chlouverakis</dc:creator>
<dc:creator>Gheorghe-Andrei Dan</dc:creator>
<dc:creator>Wolfgang Dichtl</dc:creator>
<dc:creator>Hans Christoph Diener</dc:creator>
<dc:creator>Alexander Fierenz</dc:creator>
<dc:creator>Andreas Goette</dc:creator>
<dc:creator>Joris R de Groot</dc:creator>
<dc:creator>Astrid Hermans</dc:creator>
<dc:creator>Andrzej Lubinski</dc:creator>
<dc:creator>Eloi Marijon</dc:creator>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Lluís Mont</dc:creator>
<dc:creator>Ann-Kathrin Ozga</dc:creator>
<dc:creator>Kim Rajappan</dc:creator>
<dc:creator>Andrea Sarkozy</dc:creator>
<dc:creator>Daniel Scherr</dc:creator>
<dc:creator>Renate B Schnabel</dc:creator>
<dc:creator>Ulrich Schotten</dc:creator>
<dc:creator>Emmanuel Simantirakis</dc:creator>
<dc:creator>Tobias Toennis</dc:creator>
<dc:creator>Panos Vardas</dc:creator>
<dc:creator>Dan Wichterle</dc:creator>
<dc:creator>Antonia Zapf</dc:creator>
<dc:creator>Paulus Kirchhof</dc:creator>
<dc:date>2024-04-09</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial</dc:title>
<dc:identifier>pmid:38591192</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae225</dc:identifier>
</item>
<item>
<title>Effect of CSL112 on Recurrent Myocardial Infarction and Cardiovascular Death: Insights from the AEGIS-II Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588930/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: While CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis-related MI compared to placebo. These findings could suggest a role of apoA-I in reducing subsequent plaque disruption events via enhanced cholesterol efflux. Further prospective data would be needed to confirm these observations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 25:S0735-1097(24)06702-0. doi: 10.1016/j.jacc.2024.03.396. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction (MI) among high-risk patients with MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This exploratory analysis evaluates the effect of CSL112 therapy on the incidence of CV death and recurrent MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The AEGIS-II trial was an international, multicenter, randomized, double-blind, placebo-controlled trial that randomized 18,219 high-risk acute MI patients to 4 weekly infusions of apoA-I (6g CSL112) or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The incidence of the composite of cardiovascular death and type 1 MI was 11-16% lower in the CSL112 group over the study period (HR of 0.84 [95% CI 0.7-1.0; p=0.056] day 90, HR 0.86, [95% CI 0.74-0.99; p=0.048] day 180, and HR 0.89, [95% CI 0.79-1.01 p=0.07; p=0.07] day 365). Similarly, the incidence of CV death or any MI was numerically lower in CSL112 treated patients throughout the follow-up period (HR 0.92 [95% CI 0.8-1.05], 0.89 [95% CI 0.79-0.996], 0.91 [0.82-1.01]. The effect of CSL112 treatment on MI was predominantly observed for type 1 MI and type 4b (MI due to stent thrombosis).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: While CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis-related MI compared to placebo. These findings could suggest a role of apoA-I in reducing subsequent plaque disruption events via enhanced cholesterol efflux. Further prospective data would be needed to confirm these observations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588930/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38588930</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.396>10.1016/j.jacc.2024.03.396</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588930</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Thomas J Povsic</dc:creator>
<dc:creator>Serge Korjian</dc:creator>
<dc:creator>M Cecilia Bahit</dc:creator>
<dc:creator>Gerald Chi</dc:creator>
<dc:creator>Danielle Duffy</dc:creator>
<dc:creator>John H Alexander</dc:creator>
<dc:creator>Dragos Vinereanu</dc:creator>
<dc:creator>Pierluigi Tricoci</dc:creator>
<dc:creator>Sojaita Jenny Mears</dc:creator>
<dc:creator>Lawrence I Deckelbaum</dc:creator>
<dc:creator>Marc Bonaca</dc:creator>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Jan H Cornel</dc:creator>
<dc:creator>Basil S Lewis</dc:creator>
<dc:creator>Alexander Parkhomenko</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Philip Aylward</dc:creator>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:creator>Mark Heise</dc:creator>
<dc:creator>Frank Sacks</dc:creator>
<dc:creator>Jose C Nicolau</dc:creator>
<dc:creator>Bela Merkely</dc:creator>
<dc:creator>Jaroslaw Trebacz</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Stuart Pocock</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>John Kastelein</dc:creator>
<dc:creator>Christophe Bode</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>P Gabriel Steg</dc:creator>
<dc:creator>Michal Tendera</dc:creator>
<dc:creator>Kevin R Bainey</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Daniel Duerschmied</dc:creator>
<dc:creator>Bronwyn A Kingwell</dc:creator>
<dc:creator>C Michael Gibson</dc:creator>
<dc:creator>AEGIS-II Committees and Investigators(∗∗)</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effect of CSL112 on Recurrent Myocardial Infarction and Cardiovascular Death: Insights from the AEGIS-II Trial</dc:title>
<dc:identifier>pmid:38588930</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.396</dc:identifier>
</item>
<item>
<title>Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588929/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with AMI, severity of LV dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range of LVEF with and without congestion.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)06757-3. doi: 10.1016/j.jacc.2024.03.405. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-cause mortality when started within 14 days of acute myocardial infarction (AMI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the association between left ventricular ejection fraction (LVEF), congestion, or both on outcomes and the impact of empagliflozin in reducing HF risk post-MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the EMPACT-MI trial, patients were randomized within 14 days of an AMI complicated by either newly reduced LVEF&lt;45%, congestion, or both to empagliflozin 10 mg daily or placebo and followed for a median of 17.9 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6522 patients, the mean baseline LVEF was 41%+9%; 2648 patients (40.6%) presented with LVEF&lt;45% alone, 1483 (22.7%) presented with congestion alone, and 2181 (33.4%) presented with both. Among patients in the placebo arm, multivariable adjusted risk for each 10-point reduction in LVEF included all-cause death or HF hospitalization (hazard ratio [HR] 1.49; 95%CI, 1.31-1.69; P&lt;0.0001), first HF hospitalization (HR, 1.64; 95%CI, 1.37-1.96; P&lt;0.0001), and total HF hospitalizations (rate ratio [RR], 1.89; 95%CI, 1.51-2.36; P&lt;0.0001). Presence of congestion was also associated with a significantly higher risk for each of these outcomes (HR 1.52, 1.94, and RR 2.03, respectively). Empagliflozin reduced the risk for first (HR 0.77, 95%CI 0.60-0.98) and total (RR 0.67, 95%CI 0.50-0.89) HF hospitalization, irrespective of LVEF or congestion or both. The safety profile of empagliflozin was consistent across baseline LVEF and irrespective of congestion status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with AMI, severity of LV dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range of LVEF with and without congestion.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588929/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38588929</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.405>10.1016/j.jacc.2024.03.405</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588929</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Jacob A Udell</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Josephine Harrington</dc:creator>
<dc:creator>Michaela Mattheus</dc:creator>
<dc:creator>Svenja Seide</dc:creator>
<dc:creator>Offer Amir</dc:creator>
<dc:creator>M Cecilia Bahit</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:creator>Yundai Chen</dc:creator>
<dc:creator>Vijay K Chopra</dc:creator>
<dc:creator>Gemma Figtree</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:creator>Shaun G Goodman</dc:creator>
<dc:creator>Nina Gotcheva</dc:creator>
<dc:creator>Shinya Goto</dc:creator>
<dc:creator>Tomasz Gasior</dc:creator>
<dc:creator>Waheed Jamal</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Myung Ho Jeong</dc:creator>
<dc:creator>Yuri Lopatin</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Monica Martinez-Traba</dc:creator>
<dc:creator>Puja B Parikh</dc:creator>
<dc:creator>Alexander Parkhomenko</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Xavier Rossello</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Dragan Simic</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Joanna Szachniewicz</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Dragos Vinereanu</dc:creator>
<dc:creator>Shelley Zieroth</dc:creator>
<dc:creator>Martina Brueckmann</dc:creator>
<dc:creator>Mikhail Sumin</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction</dc:title>
<dc:identifier>pmid:38588929</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.405</dc:identifier>
</item>
<item>
<title>Remote Acute Assessment of Cardiac Patients Post-Acute Coronary Syndrome (TELE-ACS): A Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588928/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The TELE-ACS study has shown that a telemedicine-based approach for the management of patients following ACS was associated with a reduction in hospital readmission, ED visits, unplanned coronary revascularization and patient reported symptoms.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 28:S0735-1097(24)06709-3. doi: 10.1016/j.jacc.2024.03.398. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Telemedicine programmes can provide remote diagnostic information to aid clinical decision that could optimize care and reduce unplanned re-admissions post ACS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: TELE-ACS is a randomized controlled trial which aims to compare a telemedicine-based approach versus standard care in patients following ACS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients were suitable for inclusion with at least one cardiovascular risk factor and presenting with ACS and were randomized (1:1) prior to discharge. The primary outcome was time to first readmission at 6-months. Secondary outcomes included emergency department (ED) visits, major adverse cardiovascular events and patient reported symptoms. The primary analysis was performed according to intention to treat. The trial was registered on ClinicalTrial.gov (NCT05015634).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 337 patients were randomized from January 2022 to April 2023, with a 3.6% drop-out rate. The mean age was 58.1 years. There was a reduced rate of readmission over 6-months (hazard ratio [HR] 0.24; 95% confidence interval [CI] 0.13 to 0.44; p &lt; 0.001) and ED attendance (HR 0.59; 95% CI 0.59; 95% CI 0.40 to 0.89) in the telemedicine arm, and fewer unplanned coronary revascularizations (3% in telemedicine arm versus 9% in standard therapy arm). The occurrence of chest pain (9% versus 24%), breathlessness (21% versus 39%) and dizziness (6% versus 18%) at 6-months was lower in the telemedicine group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The TELE-ACS study has shown that a telemedicine-based approach for the management of patients following ACS was associated with a reduction in hospital readmission, ED visits, unplanned coronary revascularization and patient reported symptoms.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588928/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38588928</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.398>10.1016/j.jacc.2024.03.398</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588928</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Nasser S Alshahrani</dc:creator>
<dc:creator>Adam Hartley</dc:creator>
<dc:creator>James Howard</dc:creator>
<dc:creator>Reza Hajhosseiny</dc:creator>
<dc:creator>Saud Khawaja</dc:creator>
<dc:creator>Henry Seligman</dc:creator>
<dc:creator>Tamim Akbari</dc:creator>
<dc:creator>Badr A Alharbi</dc:creator>
<dc:creator>Paul Bassett</dc:creator>
<dc:creator>Rasha Al-Lamee</dc:creator>
<dc:creator>Darrel Francis</dc:creator>
<dc:creator>Amit Kaura</dc:creator>
<dc:creator>Mihir A Kelshiker</dc:creator>
<dc:creator>Nicholas S Peters</dc:creator>
<dc:creator>Ramzi Khamis</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Remote Acute Assessment of Cardiac Patients Post-Acute Coronary Syndrome (TELE-ACS): A Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:38588928</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.398</dc:identifier>
</item>
<item>
<title>Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588927/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: One in 4 patients with HFrEF were classified as at least high KDIGO kidney risk; these individuals faced concordantly the highest risks of CV events. Sacubitril/valsartan exhibited consistent CV and kidney protective benefits as well as safety across the spectrum of baseline kidney risk. These data further support initiation of sacubitril/valsartan in HFrEF across a broad range of kidney risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)06691-9. doi: 10.1016/j.jacc.2024.03.392. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The Kidney Disease Improving Global Outcomes (KDIGO) classification integrates both estimated glomerular filtration rate(eGFR) and urine-albumin-creatinine-ratio to stratify risk more comprehensively in patients with chronic kidney disease. There are limited data assessing whether this classification system is associated with prognosis and treatment response in heart failure populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PARADIGM-HF was a global RCT evaluating sacubitril/valsartan vs. enalapril in patients with HFrEF. Patients were classified according to low, moderate, and high/very high KDIGO risk. Treatment responses were assessed according to baseline KDIGO risk. The primary outcome was a composite of CV death or HF hospitalization. A renal composite outcome was defined as sustained decline in eGFR by ≥40% or end stage kidney disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 1,910 (23% of total) participants with available data, 42%, 32%, and 26% were classified as low, moderate, and high/very high KDIGO risk, respectively. Patients in the highest KDIGO risk categories experienced the highest rates of the primary composite outcome (7.6[6.5-9.0], 9.4[7.9-11.2], 14.9[12.7-17.6] per 100py; P&lt;0.001). Sacubitril/valsartan had a similar safety profile and similarly reduced the risk of both the primary outcome (P<sub>Interaction</sub>=0.31) and the renal composite outcome (P<sub>Interaction</sub>=0.50) across the spectrum of KDIGO risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: One in 4 patients with HFrEF were classified as at least high KDIGO kidney risk; these individuals faced concordantly the highest risks of CV events. Sacubitril/valsartan exhibited consistent CV and kidney protective benefits as well as safety across the spectrum of baseline kidney risk. These data further support initiation of sacubitril/valsartan in HFrEF across a broad range of kidney risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588927/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38588927</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.392>10.1016/j.jacc.2024.03.392</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588927</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Brendon L Neuen</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Iris E Beldhuis</dc:creator>
<dc:creator>Finnian R Mc Causland</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Jean L Rouleau</dc:creator>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>Martin P Lefkowitz</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>John Jv McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure</dc:title>
<dc:identifier>pmid:38588927</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.392</dc:identifier>
</item>
<item>
<title>Mandibular Advancement vs CPAP for Blood Pressure Reduction in Patients with Obstructive Sleep Apnea</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588926/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: MAD is non-inferior to CPAP for reducing 24-hour mean arterial BP in participants with hypertension and increased cardiovascular risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 13:S0735-1097(24)00906-9. doi: 10.1016/j.jacc.2024.03.359. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertension guidelines recommend diagnosis and treatment of obstructive sleep apnea (OSA) in patients with hypertension. The mandibular advancement device (MAD) is an oral appliance therapy for patients who decline or cannot tolerate CPAP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: We compared the relative effectiveness of MAD versus CPAP in reducing 24-hour ambulatory BP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In an investigator-initiated, randomized, non-inferiority trial (pre-specified margin 1.5 mmHg), 321 participants, aged over 40, with hypertension and increased cardiovascular risk were recruited at 3 public hospitals for polysomnography. Of these, 220 participants with moderate-to-severe OSA (apnea-hypopnea index (AHI) ≥15 events/hour) were randomized to either MAD or CPAP (1:1). The primary outcome was the difference between the 24-hour mean arterial BP at baseline and 6 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared to baseline, the 24-hour mean arterial BP decreased by 2.5 mmHg (P = 0.003) at 6 months in the MAD group, whereas no change was observed in the CPAP group (P = 0.374). The between-group difference was -1.6 mmHg (95% confidence interval: -3.51 to 0.24, non-inferiority P &lt; 0.001). The MAD group demonstrated a larger between-group reduction in all secondary ambulatory BP parameters compared to the CPAP group, with the most pronounced effects observed in the asleep BP parameters. Both the MAD and CPAP improved daytime sleepiness, with the between-group difference similar (P = 0.384). There were no between-group differences in cardiovascular biomarkers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: MAD is non-inferior to CPAP for reducing 24-hour mean arterial BP in participants with hypertension and increased cardiovascular risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588926/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38588926</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.359>10.1016/j.jacc.2024.03.359</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588926</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Yi-Hui Ou</dc:creator>
<dc:creator>Juliana Tereza Colpani</dc:creator>
<dc:creator>Crystal S Cheong</dc:creator>
<dc:creator>Weiqiang Loke</dc:creator>
<dc:creator>As Tar Thant</dc:creator>
<dc:creator>E Ching Shih</dc:creator>
<dc:creator>Frank Lee</dc:creator>
<dc:creator>Siew-Pang Chan</dc:creator>
<dc:creator>Ching-Hui Sia</dc:creator>
<dc:creator>Chieh-Yang Koo</dc:creator>
<dc:creator>Serene Wong</dc:creator>
<dc:creator>Aiping Chua</dc:creator>
<dc:creator>Chin-Meng Khoo</dc:creator>
<dc:creator>William Kong</dc:creator>
<dc:creator>Calvin W Chin</dc:creator>
<dc:creator>Pipin Kojodjojo</dc:creator>
<dc:creator>Philip E Wong</dc:creator>
<dc:creator>Mark Y Chan</dc:creator>
<dc:creator>A Mark Richards</dc:creator>
<dc:creator>Peter A Cistulli</dc:creator>
<dc:creator>Chi-Hang Lee</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Mandibular Advancement vs CPAP for Blood Pressure Reduction in Patients with Obstructive Sleep Apnea</dc:title>
<dc:identifier>pmid:38588926</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.359</dc:identifier>
</item>
<item>
<title>Right Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588337/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):1169-1171. doi: 10.1161/CIRCULATIONAHA.124.067985. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588337/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38588337</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.067985>10.1161/CIRCULATIONAHA.124.067985</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588337</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Sharmila Dorbala</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Right Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy</dc:title>
<dc:identifier>pmid:38588337</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.067985</dc:identifier>
</item>
<item>
<title>Correction to: Telehealth: Lessons Learned From the Pandemic and Keys to Effective Research and Policy Design</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588336/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):e1108. doi: 10.1161/CIR.0000000000001246. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588336/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38588336</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001246>10.1161/CIR.0000000000001246</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588336</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Telehealth: Lessons Learned From the Pandemic and Keys to Effective Research and Policy Design</dc:title>
<dc:identifier>pmid:38588336</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001246</dc:identifier>
</item>
<item>
<title>Hemodynamic Forces and Atherosclerosis: HEG1 at the Center of the Jigsaw Puzzle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588335/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):1202-1204. doi: 10.1161/CIRCULATIONAHA.124.067882. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588335/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38588335</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.067882>10.1161/CIRCULATIONAHA.124.067882</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588335</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>M Luisa Iruela-Arispe</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Hemodynamic Forces and Atherosclerosis: HEG1 at the Center of the Jigsaw Puzzle</dc:title>
<dc:identifier>pmid:38588335</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.067882</dc:identifier>
</item>
<item>
<title>Single-Cell Multimodal Profiling of Atherosclerosis Identifies CD200 as a Cell Surface Lineage Marker of Vascular Smooth Muscle Cells and Their Derived Cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588334/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):1231-1233. doi: 10.1161/CIRCULATIONAHA.123.067092. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588334/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38588334</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067092>10.1161/CIRCULATIONAHA.123.067092</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588334</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Bashore</dc:creator>
<dc:creator>Allen Chung</dc:creator>
<dc:creator>Chinyere Ibikunle</dc:creator>
<dc:creator>Hanying Yan</dc:creator>
<dc:creator>Chenyi Xue</dc:creator>
<dc:creator>Mingyao Li</dc:creator>
<dc:creator>Robert C Bauer</dc:creator>
<dc:creator>Muredach P Reilly</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Single-Cell Multimodal Profiling of Atherosclerosis Identifies CD200 as a Cell Surface Lineage Marker of Vascular Smooth Muscle Cells and Their Derived Cells</dc:title>
<dc:identifier>pmid:38588334</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067092</dc:identifier>
</item>
<item>
<title>Summarizing Primary Results in Clinical Trials With a Time-to-Event End Point: Complementing Different Measures for a Comprehensive Assessment of Treatment Effect</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38588333/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240409180720&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 9;149(15):1154-1156. doi: 10.1161/CIRCULATIONAHA.123.068037. Epub 2024 Apr 8.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38588333/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240409180720&v=2.18.0.post9+e462414">38588333</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.068037>10.1161/CIRCULATIONAHA.123.068037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38588333</guid>
<pubDate>Mon, 08 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Andrea Bellavia</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:date>2024-04-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Summarizing Primary Results in Clinical Trials With a Time-to-Event End Point: Complementing Different Measures for a Comprehensive Assessment of Treatment Effect</dc:title>
<dc:identifier>pmid:38588333</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.068037</dc:identifier>
</item>





























</channel>
</rss>